CAJ | 학술논문

目的：探讨甲钴胺治疗尿毒症性周围神经病变的疗效。方法：选择2012年1月～2012年12月本院100例尿毒症性周围神经病变患者。采用随机对照试验分为研究组与对照组，研究组采用甲钴胺，对照组采用维生素B12治疗，观察治疗6个月后临床症状体征变化、神经传导速度的变化及采用SF-36量表评估治疗前后尿毒症周围神经病变患者的生活质量变化，并与对照组进行比较。结果：治疗6个月后研究组“四肢远端的麻木与烧灼感”、“自发性疼痛”、“膝腱反射消失”、“四肢感觉减退”的发生率较对照组显著降低（ P均<0．05）。研究组治疗后正中神经的感觉神经传导速度（ SCV）、运动神经传导速度（MCV）较对照组相比差异有统计学意义，腓总神经方面差异无统计学意义（ P>0．05）。治疗后研究组SF-36量表中“SF-36总分”、“生理功能”、“生理职能”、“躯体疼痛”差异有统计学意义，其余差异无统计学意义。结论：在维持性血液透析的尿毒症性周围神经病变患者中，甲钴胺可作为血液透析治疗基础上重要的辅助治疗药物。
목적：탐토갑고알치료뇨독증성주위신경병변적료효。방법：선택2012년1월～2012년12월본원100례뇨독증성주위신경병변환자。채용수궤대조시험분위연구조여대조조，연구조채용갑고알，대조조채용유생소B12치료，관찰치료6개월후림상증상체정변화、신경전도속도적변화급채용SF-36량표평고치료전후뇨독증주위신경병변환자적생활질량변화，병여대조조진행비교。결과：치료6개월후연구조“사지원단적마목여소작감”、“자발성동통”、“슬건반사소실”、“사지감각감퇴”적발생솔교대조조현저강저（ P균<0．05）。연구조치료후정중신경적감각신경전도속도（ SCV）、운동신경전도속도（MCV）교대조조상비차이유통계학의의，비총신경방면차이무통계학의의（ P>0．05）。치료후연구조SF-36량표중“SF-36총분”、“생리공능”、“생리직능”、“구체동통”차이유통계학의의，기여차이무통계학의의。결론：재유지성혈액투석적뇨독증성주위신경병변환자중，갑고알가작위혈액투석치료기출상중요적보조치료약물。
Objective:To investigate the efficacy of mecobalamin in patients with uremic peripheral neuropathy were collect-ed. Methods:Randomized controlled trials were taken and patients were randomly divided into the study group and the control group. Mecobalamin was used in the study group and vitamin B12 treatment in control group. Clinical symptoms and changes of nerve conduc-tion velocity were observed after 6 months of treatment. The SF-36 scale was used to assess the quality of life of patients with uremic peripheral neuropathy after treatment,and it was compared with the control group. Results:After 6 months of treatment,in study group,the incidence of“distal limb numbness and burning sensation”,“spontaneous pain”,“knee jerk reflex”,“limb hypoesthe-sia”were significantly decreased than the control group(P<0. 05). After treatment in study group,sensory nerve conduction velocity ( SCV),motor nerve conduction velocity( MCV)in median nerve was statistically different with the control group. But no significant difference was found in the common peroneal nerve(P>0. 05). After treatment in the study group“SF-36 scores”,“physical func-tion”,“role physical”,“bodily pain”in the SF-36 scale was significantly different,but the rest was no significantly different. Conclusion:In uremic hemodialysis patients with peripheral neuropathy,mecobalamin can be used as hemodialysis treatment on the basis of important drug adjuvant therapy.